Could the mosaic pattern of chromosomal abnormality predict overall survival of patients with myelodysplastic syndrome?
Open Access
- 1 June 2016
- journal article
- Published by Medknow in Hematology/Oncology and Stem Cell Therapy
- Vol. 9 (2) , 41-47
Abstract
Objective/background: Myelodysplastic syndromes (MDSs) are a group of monoclonal hematopoietic diseases consisting of a number of various entities. The presence of differences in chromosomal content of cells within the same individual is known as chromosomal mosaicism . The impact of mosaic pattern on the prognosis of MDS has been unclear. In this study, we aimed to determine the impact of mosaic pattern on the survival of patients with MDS. Methods: We retrospectively evaluated 119 patients diagnosed with MDS at the Trakya University Faculty of Medicine, Department of Hematology. Giemsa-Trypsin-Giemsa banding was used to evaluate chromosomal abnormality. The effect of chromosomal abnormality mosaicism on overall survival and transformation to acute leukemia was evaluated by Kaplan-Meier survival analysis. Results: The mean age at diagnosis was 66.3 years, and the mean disease duration was 24.2 months. Chromosomal abnormality was observed in 32.5% of patients. Patients with chromosomal abnormalities comprising at least 50% metaphases had significantly lower overall survival than patients with abnormality comprising up to 50% of all abnormal metaphases ( p = .003). There were no differences in transformation to acute leukemia among patients with higher and lower chromosomal mosaicism ( p = .056). Conclusion: The most important outcome of this study was to demonstrate worse overall survival rates in MDS patients with higher abnormal chromosomal mosaicism than patients with lesser abnormal chromosomal mosaicism. Higher levels of abnormal chromosomal mosaicism did not predict transformation to acute leukemia. The cause of worse outcomes of patients with higher abnormal chromosomal mosaicism may be related to clonal mass.Keywords
This publication has 25 references indexed in Scilit:
- Prognostic models in myelodysplastic syndromesHematology-American Society Hematology Education Program, 2013
- Morphology, cytogenetics and classification of MDSBest Practice & Research Clinical Haematology, 2013
- Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromesAmerican Journal of Hematology, 2013
- Prognostic scoring systems in MDSLeukemia Research, 2012
- Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromesAmerican Journal of Hematology, 2012
- Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Haematologica, 2011
- Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignanciesBlood, 2011
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changesBlood, 2009
- New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patientsBlood, 2007
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982